$PLRZJun 29, 2026, 12:44 PMAI processed
PLRZ: Central IRB approves NASARIX seasonal-allergy clinical study
AI Summary
Polyrizon (PLRZ) received central IRB approval from BRANY to begin its first human trial of NASARIX, an intranasal hydrogel meant to block airborne allergens; the randomized study will compare NASARIX against saline to assess efficacy, safety and tolerability in seasonal allergic rhinitis. The approval covers the master protocol and study materials and is valid through June 17, 2027.
Positives
- Central IRB (BRANY) approved the master protocol for the first-in-human NASARIX study
- Study is a controlled comparison versus saline aimed at efficacy, safety and tolerability endpoints
- Master protocol, informed consent, QoL tools and e-diary were all approved (approval valid through 17-Jun-2027)
Negatives
- Individual clinical sites still need site-specific IRB approvals before activation or enrollment
- No clinical data yet — this is a first-in-human, early-stage study
- Approval is IRB-level; no regulatory trial clearance (e.g., FDA) is mentioned